How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
DBS Devices for Parkinson’s Disease Market
- By Device Type: Rechargeable DBS Systems, Non-Rechargeable DBS Systems, Directional DBS Leads, Omnidirectional DBS Leads
- By Target Brain Region: Subthalamic Nucleus (STN), Globus Pallidus Internus (GPi), Thalamus (VIM)
- By Application: Symptom Management, Motor Fluctuation Control, Medication Reduction
- By End User: Hospitals and Clinics, Specialized Neurology Centers, Ambulatory Surgical Centers
- By Technology Platform: Closed-Loop DBS Systems, Open-Loop DBS Systems
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Rechargeable DBS Systems leads By Device Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.170 →
- 12 Company Profiles 10 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the DBS Devices for Parkinson’s Disease Market report
A complete, evidence-based study - 12 chapters and 113 sections covering market size, segmentation across 5 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →LivaNova PLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →SceneRay Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →NeuroPace Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Aleva Neurotherapeutics SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →St. Jude Medical (now part of Abbott)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Bioness Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Functional Neuromodulation Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Rechargeable DBS Systems54.8
- Non-Rechargeable DBS Systems10.1
- Directional DBS Leads21.0
- Omnidirectional DBS Leads14.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic plc11.9
- Abbott Laboratories24.5
- Boston Scientific Corporation7.8
- LivaNova PLC7.0
- SceneRay Co. Ltd.11.5
- NeuroPace Inc.9.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.7
- Europe24.0
- Asia Pacific21.3
- Latin America11.5
- Middle East and Africa10.6
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic plc | 76 | 83 | 77 | 98 | 94 | 98 | 88 |
| Abbott Laboratories | 69 | 71 | 84 | 85 | 72 | 85 | 78 |
| Boston Scientific Corporation | 65 | 73 | 79 | 80 | 67 | 78 | 74 |
| LivaNova PLC | 70 | 80 | 81 | 61 | 60 | 71 | 71 |
| SceneRay Co. Ltd. | 63 | 55 | 61 | 74 | 53 | 65 | 62 |
| NeuroPace Inc. | 66 | 67 | 55 | 69 | 52 | 58 | 61 |
| Aleva Neurotherapeutics SA | 52 | 58 | 58 | 62 | 63 | 60 | 59 |
| St. Jude Medical (now part of Abbott) | 49 | 37 | 40 | 50 | 42 | 53 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic plc
- Abbott Laboratories
- Boston Scientific Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic plc | ◐ | ◐ | ◐ | ✓ | ✓ | ✓ |
| Abbott Laboratories | ◐ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Boston Scientific Corporation | − | ✓ | ◐ | ✓ | ✓ | ◐ |
| LivaNova PLC | ◐ | ◐ | ✓ | − | − | ✓ |
| SceneRay Co. Ltd. | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| NeuroPace Inc. | − | ◐ | − | ◐ | − | ◐ |
| Aleva Neurotherapeutics SA | − | − | − | ◐ | ◐ | ◐ |
| St. Jude Medical (now part of Abbott) | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Challenger2
Strong scale, closing on the leaders.
Contender3
Focused players with pockets of strength.
Niche1
Specialists in a single segment or region.
Go-to-market strategy
Land Device Type in North America, then scale across DBS Devices for Parkinson’s Disease Market — a $428M beachhead inside a $5.97B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Rechargeable DBS Systems
Best fit — highest urgency & budget in Device Type.
Non-Rechargeable DBS Systems
Strong fit — clear ROI and a fast path to value.
Directional DBS Leads
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Device Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Target Brain Region & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Device Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win DBS Devices for Parkinson’s Disease Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
DBS Devices for Parkinson’s Disease Market is a durable-growth opportunity — $1.59B by 2033, compounding at 8.8%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.8% CAGR
Demand compounds through 2033, outpacing GDP across Device Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Device Type moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Target Brain Region optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
DBS Devices for Parkinson’s Disease Market — a $4.16B market by 2033. Plan: grow share from 7.6% to 11.9%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.6% | 11.9% | At risk |
| Revenue | $331M | $495M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 31.3% | 40.3% | On track |
| Customer retention | 89.5% | 94.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Device Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Target Brain Region capability
A defensible second engine — invest in Target Brain Region to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Device Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Target Brain Region
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $69M capacity & capability investment
- Greenlight bolt-on M&A in Target Brain Region
- Authorise North America expansion plan
- Fund R&D program for Device Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeBehind
- Execution & talentBehind
Sales deck · value proposition
Win the DBS Devices for Parkinson’s Disease Market conversation — a $1.58B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Device Type
Goal Grow share in Device Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your DBS Devices for Parkinson’s Disease Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
DBS Devices for Parkinson’s Disease Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Prescription Lenses Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportPrescription Glasses Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportD-Biotin Powder Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportDay Surgery Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportDaylight Therapy Lamp Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportIPL (Intense Pulsed Light) Devices Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportDay Case Surgery Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportElectrolytic Ozone Disinfection Machine Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportDavis Mouth Gags Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportIntense Pulsed Light Hair Removal Machines Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportDaunorubicin Hydrochloride Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportDaunorubicin Hydrochloride Injection Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy